(S023) The Radium Chemical Company: 1913–1981

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

The Standard Chemical Company was organized in 1911 to produce and sell radium. It was the first American company to do so. Most of the radium went to Europe, as there was little demand in America.

Roger F. Robison, MD; Good Samaritan Hospital

The Standard Chemical Company was organized in 1911 to produce and sell radium. It was the first American company to do so. Most of the radium went to Europe, as there was little demand in America. Therefore, in 1913, Standard formed a subsidiary, Radium Chemical Company (RCC), for marketing and sales promotion. The RCC published a monthly journal, Radium, during 1913–1925 and supported the establishment of the American Radium Society. They also manufactured sealed radium sources and brachytherapy devices. During World War I (1914–1918), the production of luminous paint for military equipment and timepieces utilized 50% of all of the radium produced by Standard and its competitors. Yearly sales of radioluminescent watches and clocks skyrocketed from 8,500 in 1913 to 4 million in 1920.

Belgium Radium took over the market in 1922–1923. Standard ceased mining operations and was slowly liquidated during 1928–1933. However, the RCC continued with paint production, dial painting, and the manufacturing of sealed sources and devices. The manufacturing site in Queens, NY was shut down in 1981. When it was demolished during 1988–1995, the Environmental Protection Agency found 10,000 radium needles, 120 grams of radium, 189 Ci of radioactive waste, 92 tons and 197 gallons of nonradioactive hazardous waste, and 812 tons of radioactive soil and debris.

Workers at Radium Dial (RD), an RCC subsidiary, utilized the desks in an old school in Ottawa, IL. By 1925, they were painting 1 million dials a year. That year, the lawsuits began against US Radium in NJ, which had noted employee deaths from radium during 1922–1924. RD began secretly testing their employees and fired anyone who was sick. After six deaths, RD liquidated and moved a few blocks away to continue business as Luminous Processes (LP). LP was shut down by the Nuclear Regulatory Commission in 1978 and tried to donate their desks to a local Catholic school. 

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Related Content